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1. Introduction
Numerous German initiatives to liberalise cannabis-related criminal law have arisen 
against the backdrop of global debates, stimulating reform. Current drug policy is 
being discussed intensively, including calls to end prohibition of cannabis from well-
known criminal law professors aligning with the resolution of Prof. Dr. med. Lorenz 
Böllinger.1 Advocates cite the benefits of relieving the police and courts to focus their 
resources on organised crime. Opponents fear legalisation will increase the number 
of consumers and magnify healthcare costs at the expense of society.
In Western and Central Europe, including Germany, a market for illegal drugs 
emerged in the late 1960s,2 which has not yet been stabilised politically or socially. 
The climate favouring drug reforms is a paradigm shift. Liberalisation of drug laws 
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in the Netherlands, Switzerland, Spain, Belgium, Portugal, the Czech Republic, and 
several US states has so far not led to an increased drug use as feared.3 In 2014, Uru-
guay legislated to regulate cultivation, sale, and consumption of cannabis to deprive 
organised crime of the market and to prevent use of harder drugs.4 Cannabis has been 
grown, consumed, and sold in small quantities legally in Canada since 17 October 
2018.5 In New Zealand a not binding cannabis referendum was held on 17 October 
2020, on the question of whether to legalise the sale, use, possession and production 
of cannabis.6 
This paper aims on the one hand, to provide insights into German narcotics law. On 
the other hand, the political arguments for sticking to prohibition are contrasted with 
the numerous empirical findings that are now available. The results of the empirical 
studies now challenge the Federal Constitutional Court and the legislature to review 
their previous course and possibly break new ground in drug policy. Section 2 out-
lines the current legal situation following the findings of the German Federal Con-
stitutional Court more than 20 years ago. Section 3 critically reviews the main argu-
ments used so far to justify prohibition, namely the health and social risk assessment 
and the predicted development of consumption, in terms of their scientific content. 
Since the new scientific studies may lead to a new constitutional assessment of canna-
bis use and to a new legal situation in Germany, we trace current political advanced 
initiatives toward a new cannabis policy in Section 4. In Section 5 we give an overview 
of ‘new facts’ presented in a new submission order to the German Federal Constitu-
tional Court in April 2020. Section 6 contains our summary and conclusions.
2. Current German legal framework
The German legal framework for drugs and addiction is multi-layered because policy 
affects many spheres of life. The handling of drugs, dealing and trafficking, medical 
prescriptions, drug use, and addiction are governed by provisions set at international, 
European, and national levels. At the national level, a range of parties oversee drug 
issues. Under Germany’s federal structure, they erect cross-sectoral legal conditions 
concerning addiction and drug policy.
3 Rosmarin and Eastwood, A quiet revolution: Drug decriminalisation policies in practice across 
the globe (Release 2012) p. 13. 
4 Hudak, Ramsey and Walsh Uruguay’s cannabis law: Pioneering a new Paradigm, WOLA 
(2018) https://www.brookings.edu/wp-content/uploads/2018/03/gs_032118_uruguaye28099s-
cannabis-law_final.pdf 19. March 2021.
5 The Cannabis Act (S.C. 2018, c. 16) in Canada. Department of Justice of Canada on Cannabis 
Legalization and Regulation https://www.justice.gc.ca/eng/cj-jp/cannabis/ 19. March 2021.
6 New Zealand Government: Cannabis legalisation and control referendum https://www.justice.
govt.nz/assets/Documents/Publications/Cannabis-Legalisation-and-Control-Bill-Exposure-
Draft-for-Referendum2.pdf 28. April 2021. 
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The driving force behind the restrictive use of cannabis in Germany was international 
law: The history of the illegalisation of cannabis in Germany begins in 1929, when 
German Reichstag passed ‘The Act on the Trade in Narcotic Drugs’ (Opium Law)7 
in order to implement the so-called ‘Geneva Opium Agreement’ of 19258 signed and 
ratified by 56 countries.9 For the first time in German history the Opium Law mentioned 
dealing with ‘Indian hemp’ as a punishable offence. In 1971, Germany’s central 
national legislation was renamed to ‘Narcotic Drugs Act’ (Betäubungsmittelgesetz; 
BtMG).10 Alongside administrative regulations concerning narcotics trade, the act 
is significant practically because narcotics offences appear in the daily business of 
German courts. BtMG determines what substances are narcotics, regulates their 
trade, and sanctions their handling. Sanctions for violating its provisions include 
penalties for misdemeanours and crimes, fines for regulatory offences, rehabilitation 
and prevention measures, and administrative acts such as confiscation. Numerous 
other laws set criminal provisions and sanctions for drug-related offences, including 
the German Criminal Code,11 German Road Traffic Act,12 German Precursors 
Monitoring Act,13 and the German New Psychoactive Substances Act.14 
Plants and their constituents belonging to genus cannabis are listed in Annex I–§ 1 (1) 
BtMG and are not marketable narcotics. Central forms of action related to cannabis 
production, sale, and purchase are prohibited. Although consumption is not subject 
to sanctions, purchase and possession preceding it are subject to sanctions. A permit 
under § 3 BtMG can only be granted for scientific or purposes in the public interest. 
In March 2017, Germany legalised therapeutics containing tetrahydrocannabinol, 
mainly in the form of the flower or extracts, for patients with for instance chronic 
pain, multiple sclerosis, and cancer (§ 13 BtMG). Legalising medicinal cannabis had 
a domino effect. Portugal and Denmark followed suit, discussing the legalisation or 
7 On 10. December 1929, National Gazette I 1929, Nr. 43 p. 215.
8 International Opium Convention. Geneva, 19 February 1925. https://treaties.un.org/Pages/
ViewDetails.aspx?src=TREATY&mtdsg_no=VI-6-a&chapter=6&clang=_en 19. March 2021.
9 United Nations, Office on Drugs and Crime (UNODC), World Drug Report (2008) p.192 ff.; 
<https://www.unodc.org/documents/wdr/WDR_2008/WDR_2008_eng_web.pdf> 19. March 
2021.
10 The Act on the Trade in Narcotic Drugs in Germany, 22. December 1971, entered into force 
01. January 1972, current version 01. March 1994, Federal Law Gazette I pp. 681, 1187. http://
www.gesetze-im-internet.de/btmg_1981/ 19. March 2021.
11 Strafgesetzbuch (StGB) https://www.gesetze-im-internet.de/stgb/ 19. March 2021.
12 Straßenverkehrsgesetz (StVG) https://www.gesetze-im-internet.de/stvg/ 19. March 2021.
13 Grundstoffüberwachungsgesetz (GÜG) https://www.gesetze-im-internet.de/g_g_2008/ 19. 
March 2021.
14 Neue-psychoaktive-Stoffe-Gesetz (NpSG) https://www.gesetze-im-internet.de/npsg/ 19. March 
2021.
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initiating cannabis-related research.15 
German legislation allows dismissal of criminal cases against drug users. In this 
context the most relevant section is § 31a BtMG,16 introduced in 1992.17 If there is 
no public interest in prosecution and the offence can be considered minor, § 31a 
BtMG allows prosecutors18 to dismiss cases without consulting the court. The core 
consideration in applying § 31a BtMG is the small amount (geringe Menge) for 
personal use. ‘Small amount’ is undefined by the law but specified by the German 
federal states. The intent is to ‘improve the procedural recruitment options for the 
public prosecutor’s offices by waiving judicial approval’.19 The higher regional court 
case law and prevailing opinion in literature considers an amount of cannabis for a 
non-dependent user of up to three consumption units as ‘small’.20 In cannabis products 
up to an active ingredient content of 0.045g THC is assumed a small amount.21 That 
corresponds roughly to a gross weight of 6g if one assumes in favour of the accused of 
a very poor quality with an active ingredient content of less than 1%.22 However the 
public prosecutor’s offices in the individual federal states assess the ‘small amount’ of 
cannabis products differently. The prosecutors can currently dismiss the procedure in 
any federal state up to a gross weight of 6g of the product in accordance with section 
31a (1) sentence 1 of the BtMG. Some federal states also allow an adjustment for 
quantities up to 10g. Only the federal states of Berlin and Bremen regulation includes 
the option of setting up to a gross weight of 15g. That for a ‘small amount’ with the 
15 Aguilar, Gutiérrez, Sánchez and Nougier, Medicinal cannabis policies and practices around 
the world, International Drug Policy Consortium (2018) http://fileserver.idpc.net/library/
Medicinal%20cannabis%20briefing_ENG_FINAL.PDF 19. March 2021.
16 § 31a Betäubungsmittelgesetz (BtMG)
         Refraining from prosecution.
       ‘(1) If the subject matter of the proceedings is an offence pursuant to section 29 subsection 
1, 2 or 4, the public prosecutor’s office may refrain from prosecution if the offender’s guilt 
could be regarded as minor, if there is no public interest in a criminal prosecution and if the 
offender cultivates, produces, imports, exports, carries in transit, acquires, otherwise procures 
or possesses narcotic drugs in small quantities exclusively for his personal use. Prosecution 
should be refrained from if the offender possesses narcotic drugs in a drug consumption room 
in small quantities exclusively for his personal use, which may be tolerated pursuant to section 
10a, without being in possession of a written licence for acquisition.’ 
17 Weber, Betäubungsmittelgesetz: BtMG [Narcotic Drugs Act] (C.H. BECK 2017) § 31a para. 2.
18 Under the same conditions, the court may also refrain from punishing the offender. Section 
29 para. 5 Betäubungsmittelgesetz (BtMG): ‘The court may waive punishment if the offender 
cultivates, […] the narcotics in small quantities for personal consumption only.’
19 Bundestag printed matter (BT-Drs.) 12/934, 12. July 1991 http://dipbt.bundestag.de/doc/
btd/12/009/1200934.pdf 19. March 2021.
20 Patzak 2019 § 31a para. 23.
21 Patzak 2019 § 31a para. 22.
22 Patzak, Betäubungsmittelgesetz [Narcotic Drugs Act] in Körner & Patzak & Volkmer, (C.H 
BECK2019) § 31a para. 23.
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meaning of § 31a BtMG relevant gross weight of cannabis products can differ by 
up to 9g in a nationwide comparison.23 In order to standardise dismissal practice all 
over Germany the Ministers of the Justice of the federal states are now in favour of a 
common upper limit for cannabis products, which all states should set at 6g.24 
Germany’s ban on cannabis and threat of punishment constitute interference with 
general freedom of action by adults. In consistent case law of the Federal Constitutional 
Court, general freedom of action under Article 2 (1) of the Basic Law includes acts that 
pose health risks. Protection against self-injury can justify interference with adults’ 
general freedom of action only in particularly serious cases.25 In 1989, the Federal 
Administrative Court decided that the article contravened the comprehensive right 
of citizenship ‘to grant state authorities the power to dictate to the citizen what he has 
to do in the interests of his own protection’.26
In March 1994, the Federal Constitutional Court27 ruled that criminal cases involving 
possession, purchase, or import of small amounts of cannabis for personal use must 
be dismissed because the offender’s guilt and harm caused by the offence must be 
considered trivial. Criminal prosecution in such cases amounts to violations of 
the principle of proportionality and disrespect for the ultima ratio of criminal law. 
While defending the constitutionality of BtMG, the Federal Constitutional Court 
found large differences in dismissal rates unacceptable because they violate rights 
to equal and non-discriminatory treatment. The Constitutional Court concluded 
that infringing rights to equal treatment and proportionality could be avoided by 
implementing consistent non-prosecution policies throughout Germany in cases 
involving possession of small cannabis quantities for personal use. The 1994 Federal 
Constitutional Court decision set the standard for prosecution of personal use. It 
declared that German law enshrines a ‘ban on excessive punishment’ that had to be 
observed for minor offences involving personal use of cannabis.
23                Scientific  service of the Bundestag (WD 3 -3000 - 196/19).  Einstellung von Ermittlungsverfahren 
                         nach § 31 a Betäubungsmittelgesetz bei ‘’geringer Menge’’ Cannabis zum Eigenverbrauch [Termination 
of investigations after § 31a Narcotics Act for “small amounts” of cannabis for own consumption] 
(2019) p. 5. https://www.bundestag.de/resource/blob/662498/4660141b7e6a7a291783e0f087f003bb/
WD-3-196-19-pdf-data.pdf 24. August 2020.
24 Decision of the 89th Justice Ministers’ Conference, Item II.21 https://www.justiz.nrw.de/JM/
jumiko/beschluesse/2018/Fruehjahrskonferenz_2018/II-21-BW---Geringe-Menge-im-Sinne-
des-_-31a-BtMG.pdf 19. March 2021.
25 BVerfG, 12/21/2011, 1 BvR 2007/10 (Germany).
26 BVerwGE 82, p. 45 (48 f.) (Germany).
27 BVerfGE 90, p. 145. A translation of the decision appears at https://germanlawarchive.
iuscomp.org/?p=85 19. March 2021.
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The decision further states that ‘in view of the open criminal policy and scientific 
debate on the dangers of cannabis use and the correct way to combat them, the 
legislator has to observe and review the effects of existing law, including the experience 
of others’.28 It requested German federal states to assure a ‘basically uniform practice 
of application’ and, as a rule, to refrain from prosecution if conditions in § 31a BtMG 
apply. In short, the court affirmed cannabis prohibition as constitutional. It would not 
infringe the principles of proportionality, equality, and personal freedom.29 In dissent, 
Judge Bertold Sommer complained that BtMG was too broad and did not meet the 
principle of proportionality.30
Since 1971 only minor changes have been made to the BtMG. The core component has 
remained unchanged for 46 years: Cultivation, trading, purchase and possession of 
cannabis are punishable. The major change today with regard to the German Federal 
Courts decision in 1994 is the immense expansion of the use of cannabis in therapeutic 
treatment - especially in the therapeutic and self-medication not accompanied by a 
doctor. The findings on the effects and areas of application of cannabis in the medical 
field have now also been recognised by German Courts and lawmakers. On 6. April 
2016, the German Federal Administrative Court confirmed a state obligation with 
regard to the constitutional right to life and physical integrity for medical treatment 
with cannabis for certain clinical pictures. It also ruled that an exemption for self-
cultivation of cannabis should be granted if the narcotic is necessary for medical 
care and the plaintiff suffering from multiple sclerosis does not have an equally 
effective and affordable alternative therapy available. In 2017, as a consequence of 
the developments described, the medical use of cannabis in Germany was partially 
legalised for seriously ill patients by the law on the amendment of narcotics law and 
other regulations.31 Following a Europe-wide tendering procedure, the contract for 
the cultivation, harvesting and processing of cannabis for people over 10,400 kg was 
awarded by the Federal Agency for Medicines and Medical Products (Bundesinstitut 
für Arzneimittel und Medizinprodukte, BfArM) to two Canadian and one German 
Company32 for four years in April and May 2019. The BfArM assumed that cannabis 
will be available for government purposes from cultivation in Germany from the 
fourth quarter of 2020.33 
28 BVerfGE 90, p. 145 (194) (Germany).
29 BVerfGE 90, p. 145 (Germany).
30 BVerfGE 90, p. 145 (Germany).
31 BGBl. (Federal Law Gazette) Part I, No. 11 (2017) p. 403.
32 Press release 25. May 2019, https://www.bfarm.de/SharedDocs/Pressemitteilungen/DE/2019/
pm4-2019.html 03. September 2020.
33 Press releases 3/19 and 4/19 https://www.bfarm.de/DE/Bundesopiumstelle/Cannabis/
Cannabisagentur/_node.html 19. March 2021.
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Doctors wrote almost 60,000 prescriptions in the first quarter of 2019.34 However, the 
health insurance companies refused to cover the costs for every third prescription in 
2019.35
3. Arguments in favour of prohibition in the light of empirical studies
A debate on legalisation has so far been largely avoided by the German Drug 
Commissioners in the annually published ‘report on drugs and addiction’.36 The 
arguments for continuing to treat cannabis as an illicit drug are based primarily 
on the mental and physical impairments, and on the psychosocial and economic 
consequences of cannabis use. These are also the main arguments of the opponents 
of liberalisation. Partly the dangers are described dramatically.37 While only a few 
years ago the scientific evidence for mental and physical impairments was small and 
many claims were made on a case-by-case basis, numerous studies of varying quality 
have appeared. A systematic review (CaPRis-study) commissioned by the Federal 
Ministry of Health evaluated 2,100 international papers published in a decade.38 In the 
following, the most important political arguments for maintaining criminalisation 
based on the current state of research will be examined.
34 ‘60,000 prescriptions in the first quarter of 2019’ Fredericke Klein, 20. September 2019, Medical 
Tribune https://www.medical-tribune.de/medizin-und-forschung/artikel/60-000-rezepte-fuer-
cannabis-im-ersten-quartal-2019-ausgestellt/ 03. September 2020.
35  ‘60,000 prescriptions in the first quarter of 2019’ Fredericke Klein, 20. September 2019, Medical 
Tribune https://www.medical-tribune.de/medizin-und-forschung/artikel/60-000-rezepte-fuer-
cannabis-im-ersten-quartal-2019-ausgestellt/ 03. September 2020.
36 Drogen- und Suchtbericht der Drogenbeauftragten der Bundesregierung DSB [Drug and 
addiction report by the Federal Government‘s Drug Commissioner DSB] (2019, 2020). 
37 Habschick, Cannabis: „Legalize it” – not!, 11 Kriminalistik (2014) pp. 627-635; Hambrecht‚ 
Schöne neue Welt. Cannabis für alle [Beautiful new world. Cannabis for everyone.], 30 
Psychiatrische Praxis (2003) pp. 179-181; Duttge and Steuer, Zur fehlenden Empirie in der 
Debatte um eine Legalisierung von Cannabis [The lack of empiricism in the debate on the 
legalisation of cannabis], 33 Medizinrecht (2015) pp. 799–804; Täschner, Gedanken zum Bild 
des Haschischs in der Öffentlichkeit und zur Legalisierungsdebatte in Verantwortungsvoller 
Umgang mit Cannabis. - Medizinische, juristische und psychosoziale Perspektiven 
[Responsible use of cannabis. - Medical, legal and psychosocial perspectives], eds. Duttge et 
al. (Universitätsverlag Göttingen 2017) pp. 3-10. 
38 CaPRis ‘Cannabis: Potential und Risiken. Eine wissenschaftliche Analyse‘ [‘Cannabis: potential 
and risks. A scientific analysis’] https://www.bundesgesundheitsministerium.de/fileadmin/
Dateien/5_Publikationen/Drogen_und_Sucht/Berichte/Kurzbericht/171127_Kurzbericht_
CAPRis.pdf 19. March 2021; Hoch, Friemel and Schneider, Cannabis: Potenzial und Risiko. 
Eine wissenschaftliche Bestandsaufnahme (Springer 2019).
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3.1 Health risks
Studies assessed the health risk of cannabis as low, especially in the recreational use of 
adults, and showed lower health risks than the consumption of alcohol and nicotine.39 
Chronic cannabis use seems to increase the risk of respiratory symptoms (coughing, 
wheezing breath, sputum production, chest tightness).40 With regard to other somatic 
consequences such as cancer and cardiovascular diseases, the evidence is sparse, as 
most publications do not differentiate, or only insufficiently, between the overlapping 
effects of tobacco use and cannabis use.41 With regard to cognitive deficits of cannabis 
use (memory, attention processes, executive functions and psychomotor skills), consistent 
research results are available only with regard to acute cannabis exposure. Concerning the 
effects of chronic cannabis use on cognition there are heterogeneous findings.42 Impaired 
verbal memory, attention, and some executive functions may persist after prolonged 
abstinence.43 But according to the CaPRis-study, the risk of persistent cognitive and brain 
functional deficits is rated as rather low.44 Findings show an increased vulnerability of 
adolescents to cognitive disorders through regular cannabis use.45 So far, there is not enough 
research on the extent to which cannabis-associated deficits in cognition are persistent or 
reversible.46
39 Bonnet, Rauschzustände: Risiken und Nebenwirkungen. Im Focus: nicht-medizinisches Cannabis 
und synthetische Cannabinoide. [Intoxication states: risks and side effects. In focus: non-medical 
cannabis and synthetic cannabinoids. Addiction treatment.], 17 (02) Suchttherapie (2016) pp. 61-
70 (61); Bonnet, Specka and Scherbaum, Häufiger Konsum von nicht-medizinischem Cannabis. 
Gesundheitliche Folgen und Wirkung der Entzugsbehandlung. [Frequent consumption of non-
medical cannabis. Health consequences and effects of withdrawal treatment.], 141 (2) Deutsche 
Medizinische Wochenschrift (2016) pp. 126-131 (126); Deutsche Gesellschaft für Suchtforschung 
und Suchttherapie e.V., Stellungnahme zur Legalisierungsdebatte des nichtmedizinischen 
Cannabiskonsums.‘ [Statement on the legalisation debate on the non-medical use of cannabis.] 
(2015). https://www.dg-sucht.de/fileadmin/user_upload/pdf/stellungnahmen/Stellungnahme_
Legalisierungsdebatte_Cannabis_DG-Sucht.pdf  19. March 2021; Gantner, Jenseits der Evidenz: 
Eine Replik zur Cannabispolitik. [Beyond Evidence: A Replica to the Cannabis Policy.], 17 
Suchttherapie (2016) pp. 55-57 (55); Nutt, King and Phillips, on behalf of the Independent 
Scientific Committee on Drugs, Drug harms in the UK: a multicriteria decision analysis, 376 
The Lancet (2010) pp. 1558-1565.
40 Schneider et al., Cannabiskonsum zum Freizeitgebrauch in Cannabis: Potenzial und Risiko. Eine 
wissenschaftliche Bestandsaufnahme, eds. Hoch, Friemel and Schneider (Springer 2019) pp. 65-
264 (128). 
41 Kreuter et al., Cannabis–Positionspapier der Deutschen Gesellschaft für Pneumologie und 
Beatmungsmedizin e.V. (DGP), 70 Pneumologie (2016) pp. 87-97. Schneider et al. 2019 p. 128.
42  Schneider et al. 2019 p. 91.
43 Broyd et al., Acute and Chronic Effects of Cannabinoids on Human Cognition -A Systematic 
Review, 79 vol. 7 Biol Psychiatry (2016) pp. 557-567.
44  Schneider et al. 2019 p. 91 f.
45  Broyd et al. 2016; Fontes et al., Cannabis use before age 15 and subsequent executive functioning, 
198 Br J Psychiatry (2011) pp. 442–447.
46   Broyd et al. 2016; Schneider et al. 2019 p. 91.
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A reduced intelligence associated with regular cannabis use could not be consistently 
demonstrated.47 IQ deficits were particularly clear and persistently demonstrated 
even after a long period of abstinence (>1 year) in consumers who had already shown 
a dependency before the age of 18. No irreversible IQ reduction was found in first-
time users after the age of 18.48 Studies increasingly suggest that moderate cannabis 
use has no negative effects on the intelligence of adolescents.49 However, the chronic 
cannabis use is associated with structural changes in brain regions with a high density 
of CB1-receptors - especially amygdala and hippocampus, structures responsible for 
memory formation.50 
Studies that establish a link between cannabis use and psychotic disorders are 
inconsistent.51 Kraan et al.52 found that even among persons who fall into the high-
risk group for psychoses, there is no statistically significant long-term association 
between cannabis use and increased incidence of disease. Nevertheless, an earlier age 
at onset of cannabis use53 and higher levels of cannabis use54 seem to increase the risk 
for development of psychosis related to cannabis use. Study results indicate a dose- 
and concentration-dependent relationship.55 Also, the risk of psychotic disorders 
47   CaPRis 2017 p. 2.
48 Meier et al., Persistent cannabis users show neuropsychological decline from childhood to 
midlife, 190 (40) Proc Natl Acad Sci US (2012) pp. 2657–2664.
49 Mokrysz et al., Are IQ and educational outcomes in teenagers related to their cannabis use? A 
prospective cohort study, 30 (2) J Psychopharmacol (2016) pp. 159–168; Jackson et al., Impact 
of adolescent marijuana use on intelligence: Results from two longitudinal twin studies. 113(5) 
Proc Natl Acad Sci USA (2016) pp. 500–508. 
50  Cf. CaPRis 2017 p. 3; Schneider et al. 2019 p. 128.
51 E.g. Bonnet et al. 2016; Kraan et al., Cannabis use and transition to psychosis in individuals 
at ultra-high risk: Review and meta-analysis, 46 (4) Psychol Me (2015) pp. 673–681; Power et 
al., Genetic predisposition to schizophrenia associated with increased use of cannabis, 19 (119) 
Molecular psychiatry (2014) pp. 1201–1204; Marconi et al., Meta-analysis of the association 
between the level of cannabis use and risk of psychosis, 42(5) Schizophr Bull (2016) pp. 1262–
1269.
52 Kraan et al. 2015.
53 Hanna and Perez, Ghose Cannabis and development of dual diagnoses: A literature review, 43(4) 
Am J Drug Alcohol Abuse (2017) pp. 442–455.
54 Manrique-Garcia et al., Cannabis, schizophrenia and other non-affective psychoses: 35 years of 
follow-up of a population-based cohort, 42(6) Psychol Med (2012) pp. 1321–1328; Marconi et al. 
2016.
55 Marconi et al. 2016; Wotjak, Role of endogenous cannabinoids in cognition and emotionality, 
5(7) Mini Rev Med Chem (2005) pp. 659–670; Zanettini et al., Effects of endocannabinoid system 
modulation on cognitive and emotional behavior, 5(57) Front Behav Neurosci (2011).
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seems to be increased for persons with genetic predispositions.56 However, the causal 
role of cannabis use in the development of psychotic disorders has not yet been 
clarified.57 In general, a psychotic disorder is to be regarded as a multifactorial event 
in whose development not only environmental influences, but also genetic factors 
play an important role.58
An increased risk for mental disorders such as anxiety and depression is not proven 
by all studies; findings are also inconsistent.59 Some studies find no longitudinal 
associations between cannabis use and anxiety or depression.60 Meta-analyses and 
systematic reviews concluded that there was a modestly increased risk of depressive 
and anxiety disorders,61 and a greater risk of bipolar disorder.62 
Overall, inconsistent or incomplete findings require methodologically reliable 
longitudinal studies.63 Still it’s uncertain whether cannabis plays a causal role in the 
onset and persistence of mental disorders, adolescents with symptoms of mental 
disorders are more likely to use cannabis and alcohol and to develop problematic 
patterns of use of both drugs.64 In general, mental disorders are usually the result of 
multifactorial events rather than a single trigger.65
56 Radhakrishnan, Wilkinson and D´Souza, Gone to pot - a review of the association between 
cannabis and psychosis, (5) Frontiers in psychiatry (2014) pp. 1-24 (9); Van Winkel and Kuepper, 
Epidemiological, Neurobiological, and Genetic Clues to the Mechanisms Linking Cannabis Use 
to Risk for Nonaffective Psychosis. 10(1) Annual Review of Clinical Psychology (2014) pp. 767-
791 (784); Power et al. 2014; Verweij et al. 2017.
57 Havemann-Reinecke et al., Zur Legalisierungsdebatte des nichtmedizinischen Cannabiskonsums 
[On the legalisation debate of non-medical cannabis use], 88 Nervenarzt (2016) pp. 291-197; 
Schneider et al. 2019 p. 212.
58 Schneider et al. 2019 p. 219.
59 Blanco et al., Cannabis Use and Risk of Psychiatric Disorders. Prospective Evidence From a 
US National Longitudinal Study, 73(4) JAMA Psychiatry (2016) pp. 388-395; Danielsson et. 
al., Cannabis use, depression and anxiety: A 3-year prospective population-based study, 193 
Journal of Affective Disorders (2016) pp. 103-108; Horwood et al., Cannabis and depression: An 
integrative data analysis of four Australasian cohorts, (126) Drug and Alcohol Dependence (2012) 
pp. 369–378.
60 e.g. Blanco e al. 2016; Danielsson et al. 2016.
61 Moore et al., Cannabis use and risk of psychotic or affective mental health outcomes: a systematic 
review, 370(9584) Lancet (2007) pp. 319–328; Kedzior and Laeber, A positive association 
between anxiety disorders and cannabis use or cannabis use disorders in the general population- 
A meta-analysis of 31 studies, (14) BMC Psychiat (2014); Lev-Ran et al., The association between 
cannabis use and depression: a systematic review and meta-analysis of longitudinal studies, (44) 
Psychological Medicine (2013) pp. 797-810.
62 Schneider et al. 2019 p. 232.
63 See also CaPRis 2017 p. 2.
64 Hoch et al. 2019.
65 CaPRis 2017.
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A further argument for maintaining the criminalisation of cannabis is the psychological 
and physical dependence resulting from its use.66 Cannabis Use Disorders (CUD), 
one of the psychiatric diagnoses included in the Diagnostic and Statistical Manual 
of Mental Disorders, is generally understood as abuse or dependence. DSM-V, 
published in 2013, shifted away from the abuse/dependence paradigm toward a 
more dimensional scale that incorporates level of severity into its measurement of 
the syndrome, essentially combining the abuse and dependence criteria into one set 
for a diagnosis of disorder.67 CUD is defined as cannabis use that is associated with 
clinically significant problems ranging from mild to severe, including inability to stop 
using it despite psychosocial/ medical problems, the presence of craving, the need to 
use larger amounts to obtain the same effect (tolerance), and/or the onset of symptoms 
when its use is stopped (withdrawal).68 In the case of physical dependence, the body 
reacts with withdrawal symptoms. A first characteristic of physical dependence is the 
development of tolerance and the resulting increase in dosage. Cannabis withdrawal 
is a valid clinical syndrome (such as sweating, trembling, restlessness, irritability, 
peace) that emerges following abrupt cessation of frequent cannabis use.69 Physical 
withdrawal is comparably mild.70 Nevertheless, the addictive potential of cannabis is 
indisputably lower (6.2%) than that of legal drugs such as alcohol (11.2%) or nicotine 
(36.0%).71
Particular risk factors for the development of cannabis-related disorders including 
dependence are male gender, intensive use patterns, co-use with tobacco and early 
age at onset.72 In general, for all drugs, the early onset of substance use is related to 
66 DSB 2018.
67 Lopez and Blanco, Epidemiology of Cannabis Use Disorder in Introduction to Cannabis Use 
Disorders, eds. Montoya and Weiss (Springer 2019) pp. 7-11 (8); Montoya and Weiss, Cannabis 
Use Disorder (Springer 2019) pp. 1-6.
68 Montoya and Weiss 2019 p. 2.
69 Schlienz and Vandrey, Cannabis Withdrawal in Cannabis Use Disorder, eds. Montoya and Weiss 
(Springer 2019) pp. 93-102 (99). 
70 Soyka, Preuss and Hoch, Cannabisinduzierte Störungen [Cannabis-induced disorders], (88) 
Nervenarzt (2017) pp. 311-325 (311, 323).
71 Behrendt et al., Transitions from first substance use to substance use disorders in adolescence: is 
early onset associated with a rapid escalation?, (99) Drug and Alcohol Dependence (2009) pp. 68-
78. Scharnhorst and Honecker, Normenkontrollantrag zur Vorlage beim Bundesverfassungsgericht 
[Norm control application for submission to the Federal Constitutional Court (German Hemp 
Association] (Deutscher Hanfverband, 2019) p. 20.
72 CaPRis 2017; Hoch et al. 2019.
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an elevated risk of substance use disorder.73 Youth under the age of 18 are four to 
seven times more likely to develop CUD than adults.74 Studies show that the early 
use of cannabis poses a risk for adolescents with regard to the development of brain 
functions,75 impulse control, affect control, control of attention and concentration, 
memory, verve and social-organisational skills.76 Cannabis use during adolescence is 
associated with worse mental health.77 Also the relative risk of cannabis dependence 
is higher for adolescents.78 However, the increased demand for treatment79 cannot be 
cited as evidence of the particular risk potential among young people. The treatment 
figures initially only indicate that an addiction aid system with cannabis-specific 
services has been established in Germany over the last 10 years that is also being 
used.80
3.2 Social risks
Furthermore, it is argued that regular cannabis use leads to psychosocial problems 
for adolescents including an increase in the frequency of early school leaving, less 
university attendance and therefore fewer academic degrees.81 Indeed, meta-analyses 
and systematic reviews show that cannabis use is associated with higher school drop-
73 Blanco et al. 2016; Chen, O’Brien and Anthony, Who becomes cannabis dependent soon after 
onset of use? Epidemiological evidence from the United States: 2000-2001, 79(1) Drug and 
Alcohol Dependence (2005) pp. 11-22; Chen, Storr and Anthony, Early-onset drug use and risk 
for drug dependence problems, (34) Addict Behav (2009) pp. 319–322; DeWit et al., Age at first 
alcohol use: a risk factor for the development of alcohol disorders, (157) Am. J. Psychiatry (2000) 
pp. 745–750; Grant and Dawson, Age at onset of drug use and its association with DSM-IV drug 
abuse and dependence: results from the National Longitudinal Alcohol Epidemiologic Survey, 
(10) Journal of Substance Abuse (1998) pp. 163–173.
74 Winters and Lee, Likelihood of developing an alcohol and cannabis use disorder during youth: 
association with recent use and age, (92) Drug and Alcohol Dependence (2008) pp. 239–247.
75 Weiss et al., Building smart cannabis policy from the science up, (92) International Journal of 
Drug Policy (2017) pp. 39-49; Lubman, Cheetham and Yucel, Cannabis and adolescent brain 
development, (148) Pharmacology & Therapeutics (2015) pp. 1-16; Orr et al., Grey matter volume 
differences associated with extremely low levels of cannabis use in adolescence, 39(10) Journal of 
Neuroscience (2019) pp. 1817-1827.
76 Bonnet et al. 2016 p. 127; Havemann et al. 2016; Marconi et al. 2016; van Winkel and Kuepper 
2014 pp. 771-772.
77 Silins et al., Young adult sequelae of adolescent cannabis use: an integrative analysis, (1) Lancet 
Psychiatry (2014) pp. 286-293; Townsend et al. 2007; Gobbi et al. 2019. 
78 NAC 2017; Chen et al. 2005; 2009.
79 E.g. Bonnet and Scherbaum, Cannabisbezogene Störungen Teil I: Pharmakologie, Epidemiologie 
und Therapieverfahren [Cannabis-related disorders Part I: Pharmacology, Epidemiology and 
Therapeutic Procedures], (78) Fortschritte der Neurologie Psychiatrie (2010) pp. 297-305 (299). 
80 See Gantner 2016 pp. 55, 56; Tossmann and Gantner, Frühintervention, Beratung und Behandlung 
bei Cannabisstörungen [Early intervention, consultation and treatment for cannabis disorders], 
(17) Suchttherapie (2016) pp. 85-89 (85). 
81 DSB, 2018; DSB 2019.
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out rates and lower rates of University attendance and the successful completion of 
studies.82 But similar to the development of mental disorders, the question of causality 
between cannabis use among young people and lower educational successes cannot 
be clarified.83
Also, the argument that prohibition protects the young against developing criminal 
behaviour and the use of hard drugs remains scientifically unproven. The assumption 
that cannabis is a ‘gateway drug’ to ‘hard’ drugs is unfounded. It has been proven 
that hard drug users usually first used ‘softer’ cannabis products,84 but this causal 
chain cannot be proven in the opposite way. The number of cannabis users who later 
switch to hard drugs is low.85 On the basis of the study ‘Monitoring the future’, alcohol 
is the ‘gateway drug’ and is consumed before cigarettes and cannabis.86 The causal 
mechanisms of cannabis as gateway drug remain unclear. Nevertheless, prohibitionists 
seem influenced by the ‘gateway drug’ argument.87 But even the Federal Constitutional 
Court rejected this argument in the 1994 decision.
Studies of links between cannabis and crime yield no consistent results. Cross-
sectional studies that could prove a connection cannot make causal claims.88 Bryan, 
82 Horwood et al., Cannabis use and educational achievement: findings from three Australasian 
cohort studies, 110(3) Drug and Alcohol Dependence (2010) pp. 247–253; Macleod, The 
psychosocial consequences of drug misuse: A systematic review of longitudinal studies, (Suppl1) 
Drugs Educ Prevent Policy 12 (2005) pp. 85–89; Silins et al. 2014.
83  Schneider et al. 2019 p. 138.
84 E.g. Fergusson, Boden and Horwood ’Cannabis use and other illicit drug use: testing the cannabis 
gateway hypothesis’, (101) Addiction (2006) pp. 556–569.
85 Kreuzer and Wille, Drogen - Kriminologie und Therapie [Drugs - criminology and therapy.] 
(Hermann Luchterhand Verlag 1998) p. 29; Krumdiek, Cannabis sativa L. und das Aufleben 
alter Vorurteile [Cannabis sativa L. and the revival of old prejudices.], Neue Zeitschrift für 
Strafrecht (2008) pp. 437-444 (441); Stöver and Plenert, Entkriminalisierung und Regulierung. 
Evidenzbasierte Modelle für einen alternativen Umgang mit Drogenhandel und -konsum. 
[Decriminalization and regulation. Evidence-based models for an alternative approach to drug 
trafficking and consumption], (8) Friedrich-Ebert-Stiftung (2013) http://library.fes.de/pdf-files/
iez/10159.pdf  1. March 2019
86 Kirby and Barry, Alcohol as a gateway drug: a study of US 12th graders, 82(8) Journal of School 
Healt (2012) pp. 371-379 (372 f.).
87 Duttge and Steuer 2015 p. 801; Duttge and Steuer, Legalisierung von Cannabis: Verkommt 
Deutschland zu einer berauschten Gesellschaft? [Legalisation of cannabis: Does Germany 
turn into an intoxicated society?], (6) Zeitschrift für Rechtspolitik (2014) pp. 181-185; Duttge 
and Steuer 2014 p. 183; Habschick 2014 p. 629; Holm-Hadulla, Cannabis, ein harmloses 
Genussmittel? –  Die Verleugnung körperlicher, psychischer und sozialer Risiken in Werbung und 
populären Medien [Cannabis, a harmless stimulant? - The denial of physical, psychological and 
social social risks in advertising and popular media] in Duttge et al. (2017) pp. 13-26 (21).
88  Hoaken and Stewart, Drugs of abuse and the elicitation of human aggressive behavior, 28 (9) 
Addictive Behaviors (2003) pp. 1533-1554. 
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Del Bono and Pudney89 found that people who use cannabis as their only drug, 
without the co-use of other substances, do not commit crimes generated by the 
drug. Some longitudinal studies do associate increased risk of violence with long-
term cannabis use,90 others don’t.91 Despite inconsistent international findings, it is 
certain that cannabis use occurs predominantly in combination with alcohol and 
tobacco.92 Moreover, it is confirmed that early alcohol consumption leads to later 
increased delinquency, in particular to violent.93 But no drug in itself monocausal 
leads to criminality; drug use is embedded in complex psychosocial conditions.94 
This statement is important, especially with regard to violent offenses, whose complex 
origins are well researched in early socialization environments shaped by violence. 
89 Bryan, Del Bono and Pudney, Drug-related crime, No. 2013-08 ISER Working Paper Series 
(2013), University of Essex, Institute for Social and Economic Research (ISER), Colchester.
90  Schoeler et al., Continuity of Cannabis use and violent offending over the life course, 46(8) 
Psychological Medicine (2016) pp. 1663-1677 (1673). 
91 Baier, Schepker and Bergmann, Macht Kiffen friedlich und Saufen aggressiv?‘ [Makes smoking 
Marijuana peaceful and drinking aggressively?], 27(4) Zeitschrift für Jugendkriminalrecht und 
Jugendhilfe (2016) pp. 324-332; Green et al., Does heavy adolescent marijuana use lead to 
criminal involvement in adulthood? Evidence from a multiwave longitudinal study of urban 
African Americans, 112 (1) Drug and Alcohol Dependence (2010) pp. 117-125 (123). 
92 ESPAD Group (2016). ESPAD Report 2015: Results from the European School Survey Project 
on Alcohol and Other Drugs. Publications Office of the European Union, Luxembourg (2015).
93 Baier et al. 2016; Maldonado-Molina, Reingle and Jennings, Does alcohol use predict violent 
behaviors? The relationship between alcohol use and violence in a nationally representative 
longitudinal sample, 9(2) Youth violence and juvenile justice (2011) pp. 99-111.
94 Kreuzer, Endstation Sucht? – Wege aus der Sucht? [Last Stop Addiction? - Ways out of 
addiction?], in Mehrfach Auffällige - Mehrfach Betroffene. Erlebnisweisen und Reaktionsformen 
[Multiple Offenders - Multiple Victims. Experiences and forms of reaction], eds. Deutsche 
Vereinigung für Jugendgerichte und Jugendgerichtshilfen e.V. Schriftenreihe des DVJJ, Bd. 
18 (Forum Verlag 1900) pp. 276-297; Kreuzer, Drogen, Kriminalität und Strafrecht [Drugs, 
crime and criminal law.], (3) Zeitschrift für Jugendkriminalrecht und Jugendhilfe (2005) pp. 
235-241; Kreuzer, Zusammenhänge zwischen Drogen und Kriminalität [Connections between 
drugs and crime], (9) Forensische Psychiatrie, Psychologie, Kriminologie (2015) pp. 3-9; 
Kreuzer, Römer-Klees, and Schneider, Drugs and Delinquency: Some results of a current self-
report study of university students and of recent in-depth interviews with drug addicts in Drug 
Addiction Treatment Research. German and American Perspectives, eds. Bühringer and Platt 
(Krieger 1992) pp. 409-431.
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3.3 Protection of children and adolescents - prevention of higher 
consumption
According to a rating of European addiction experts,95 the severity of physical, 
mental and social impairments caused by cannabis was rated 18 on a scale from 0 
(no harm) to 100 (severe harm), putting cannabis in 8th place compared with other 
common drugs (behind alcohol, heroin, crack cocaine, methamphetamine, tobacco 
and amphetamine, but before GHB, methadone, benzodiazepines, ecstasy and 
hallucinogens). 
Although cannabis is a relatively harmless drug, advocates of prohibition argue with the 
general danger of the drug.96 Although this cannot be generally claimed, as the results 
show, there is agreement that children and young people are particularly vulnerable 
groups. But whether effective protection can be achieved through criminalisation or 
regulation, or how young people and children can be most effectively discouraged 
from consuming cannabis, is again highly controversial. Probably the most important 
argument against further-reaching reforms is that a regulated market sends the wrong 
signal and seduces children and young people to use cannabis.97
Two basic assumptions are made. It is claimed that prohibition has a direct positive 
effect on consumption rates, so that (1) a higher availability of cannabis and (2) a 
subsequent increase in consumption rates in the course of regulation is assumed.98 
Cannabis is the most frequently used drug. In 2018 there were 250 million cannabis 
users worldwide and 31 million in Europe. It is estimated that 91.2 million adults in 
the European Union (between 15 and 64 years) or 27.4% of this age group during 
their lifetime have tried cannabis. About 17.5 million young adults (between 15 and 
95 Amsterdam et al., European rating of drug harms, 29(6) J Psychopharmacol (2015) pp. 655–660. 
96 Sueddeutsche.de am 19.06.2020. Daniela Ludwig warnt vor Verharmlosung von 
Cannabiskonsum [Daniela Ludwig warns against trivialising the use of cannabis]. https://www.
sueddeutsche.de/gesundheit/gesundheit-berlin-daniela-ludwig-warnt-vor-verharmlosung-von-
cannabiskonsum-dpa.urn-newsml-dpa-com-20090101-200619-99-482729 19. March 2021.
97 DAZ.online am 29.07.2019. Spahn: Cannabis-Legalisierung wäre das falsche Signal [Spahn: 
Cannabis legalisation would be the wrong signal] unter https://www.deutsche-apotheker-
zeitung.de/news/artikel/2019/07/29/spahn-cannabis-legalisierung-waere-das-falsche-signal 19. 
March 2021. 
98 E.g. Duttge and Steuer, 2014; Hambrecht 2003; Thomasius, Gesundheitliche Auswirkungen von 
Cannabismissbrauch bei Jugendlichen und jungen Erwachsenen, in Duttge et al. (2017) pp. 27-46 
(39). Weber, Freigabe illegaler Drogen: Ethisch geboten oder unverantwortlich? – Kontra [Illegal 
drug release: ethically required or irresponsible? - Contra], (9) Suchttherapie (2008) pp. 170-176. 
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34 years) or 14.4% of this age group have tried cannabis in the last twelve months.99 
19% of all students between 15 to 16 years old have tried cannabis at least once.100
About a quarter of adults (between 15 and 64 years) in Germany (27.2%) report 
having used cannabis at least once in their lives.101 The prevalence of cannabis-
related disorders in 2018 is relatively low among 18 to 59-year-old men (abuse 0.7%; 
dependence 0.9%) and women (abuse 0.4%; dependence 0.3%).102 For adolescents, 
the values vary depending on the sample and the age group studied. Approximately 
each tenth young person between 12 and 17 years has already tried Cannabis at 
least once in his life.103 In the age group of young adults (between 18 and 25 years) 
the lifetime prevalence rises clearly to 46.4%. Of these, only a few are regular users 
(more than ten times in the last 12 months), as can be seen from the prevalences for 
adolescents (2.0%) and young adults (8.0%).104 If one considers the development of 
the consumption in the last years with young people and young adults, then highest 
prevalences were to be registered in the year 2004: afterwards rates decreased and rise 
since 2011 with young people, since 2016 with young adults again. Currently, the use 
experience of adolescents and young adults with cannabis is still below the high level 
of 2004.105
In order to obtain indications of whether drug policy approaches are related to 
availability and consumption, values from individual countries can be compared. 
In Europe, the lifetime prevalence rate of 15-year-old German girls and boys (15% 
and 18%, respectively) falls in the mid-range behind France, Switzerland, Italy, 
Belgium (French), England, and Spain (Health Behaviour in School-aged Children 
99 EMCDDA (European Monitoring Centre of Drugs and Drug Addiction) and Europol (2019). 
EU Drugs Markets Report. Gemeinsame EMCDDA-Europol-Veröffentlichungsreihe. Amt für 
Veröffentlichungen der Europäischen Union, Luxemburg, p. 93.
100 EMCDDA (European Monitoring Centre for Drugs and Drug Addiction) auf Basis der Daten 
der ESPAD Studie 2015 (European School Survey Project on Alcohol and Other Drugs); 
EMCDDA 2019.
101 EMCDDA 2019 p. 44.
102 Seitz et al., Trends des Substanzkonsums und substanzbezogener Störungen. Auswertung des 
Epidemiologischen Suchtsurveys von 1995 bis 2018, (116) Dtsch Arztebl Int, (2019) pp. 585-
591. 
103 Orth and Merkel, Die Drogenaffinität Jugendlicher in der Bundesrepublik Deutschland 2019. 
Rauchen, Alkoholkonsum und Konsum illegaler Drogen: aktuelle Verbreitung und Trends. 
BZgA-Forschungsbericht (Bundeszentrale für gesundheitliche Aufklärung 2020) p. 58. 
104 Ibid.
105 Ibid. p. 62.
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Study [HBSC Survey] of the World Health Organization).106 Large differences in 
consumption rates and patterns emerge within Europe and North America. 
The liberalisation of the Dutch drug law took place as early as 1976. Ownership, 
acquisition, trade, and production are not legalised, but retailing in coffee shops under 
strict conditions is not prosecuted. Adolescents are prohibited from coffee shops. 
Studies have sought evidence of increased consumption in the Netherlands, which 
has pursued liberal cannabis policies for 40 years. So far there is no evidence that 
decriminalisation of cannabis use led to an increase in use.107 Lifetime prevalences 
of 15-year-olds108 (both 15% girls and 18% boys) and 15 to 64-year-olds109 (27.2% 
Germany vs. 26.6% Netherlands) stand at German levels.
Already since June 2003, the possession of cannabis for personal use is no longer 
prosecuted in Belgium. A fine will be imposed on persons carrying less than 3g.110 
Related to the survey year 2013, the consumption prevalence of young adults aged 15 
to 34 years in Belgium was 10.1% and thus below the level of Germany of 13.3%.111 Per 
106 WHO, Growing up unequal: gender and socioeconomic differences in young people’s health 
and well-being. Health Behaviour in School-aged Children (HBSC 2016) p. 172 http://www.
euro.who.int/en/health-topics/Life-stages/child-and-adolescent-health/health-behaviour-in-
school-aged-children-hbsc/growing-up-unequal.-hbsc-2016-study-20132014-survey 19. March 
2021. 
107 Kilmer, Do Cannabis Possession Laws Influence Cannabis Use? in Ministry of Public 
Health of Belgium, eds. Cannabis 2002 report: a joint international effort at the initiative of 
the Ministers of Public Health of Belgium, France, Germany, The Netherlands, Switzerland: 
technical report of the scientific conference (2002) pp. 101-123. Brussels: Belgian Ministry 
of Public Health (2002) p.105. https://www.stop-cannabis.ch/images/stories/documents_stop_
cannabis/cannabis2002report.pdf; Neu, Betrachtungen zu einer möglichen Neuregulierung der 
Cannabispolitik in Deutschland unter Berücksichtigung der Erfahrungen aus den Niederlanden 
und Colorado [Discussing possible new regulations in German cannabis policy with special 
regard to the experiences in the Netherlands and Colorado], 86(7) Fortschritte der Neurologie 
Psychiatrie (2018) pp. 428–433; Reinarman, Cohen and Kaal, The Limited Relevance of 
Drug Policy: Cannabis in Amsterdam and in San Francisco, 94(5) American Journal of Public 
Health (2004) pp. 836-842; Reuband, Drogenkonsum und Drogenpolitik. Deutschland und 
die Niederlande im Vergleich. [Drug use and drug policy. Germany and the Netherlands in 
comparison.] (Westdt. Verlag 1992) p. 43; Simons-Morton et al., Cross-national comparison of 
adolescent drinking and cannabis use in the United States, Canada, and the Netherlands, 21(1) 
The International Journal of Drug Policy (2010) pp. 64-69.
108 WHO 2016 p. 172.
109 EMCDDA 2019 p. 93.
110 Deutscher Bundestag, Legalisierung von Cannabis Auswirkungen auf die Zahl der Konsumenten 
in ausgewählten Ländern [Legalisation of cannabis Effects on the number of users in selected 
countries] (2019) p. 6.
111 EMCDDA 2019 p. 93.
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the HBSC Survey,112 Flemish Belgium has rates of lifetime prevalence at the same level 
as in Germany (18% for 15 year-old males and 14% for 15 year-old females). Lifetime 
prevalence among Belgian adolescents aged 15 and 16 years has fallen significantly 
since the liberalisation of Belgian drug legislation, from 31% in 2003 to 18% in 2015.113 
Per the HBSC Survey, France, where cannabis use is banned but barely prosecuted, 
has the highest rates of lifetime prevalence (29% for 15 year-old males and 26% for 
15 year-old females).114 In the Czech Republic, where consumption of soft and hard 
drugs is largely an administrative offence, cannabis consumption rates were 23% 
among 15 year-old girls and boys, but no higher than in France.115
In Portugal, drug possession was decriminalised as early as 2001. Even the possession 
of a small amount of so-called hard drugs was no longer considered a criminal offence, 
but was classified as an administrative offence. Portugal’s decriminalisation model 
was associated with decreasing rates among young people.116 Later, the prevalence of 
consumption had fallen back to approximately the level of 2001.117 Compared to other 
European countries, however, consumption rates in Portugal are very low: in 2013/14 
about 10% and 13%, respectively, among 15-year-old girls and boys.118 The 12-months 
prevalence for 15-34 year olds lies at 8% in 2016.119 These and other improvements in 
Portugal’s drug situation (declining rates of intensive use and drug-related harm) are 
not only attributed to decriminalisation but also to the Commission for Dissuasion 
of Drug Addiction (CDT), health improvements and harm minimisation, so it is 
assumed that the reform was successful.120  
112 WHO 2016 p. 172.
113 Deutscher Bundestag 2019 p. 7; EMCDDA 2019 p. 93.
114 WHO 2016 p. 172.
115 Ibid.
116 Hughes and Stevens, What Can We Learn From The Portuguese Decriminalization of Illicit 
Drugs?, 50(6) British Journal of Criminology (2010) pp. 999-1022 (1017). 
117 Murkin, Drug decriminalisation in Portugal: setting the record straight, Transform (2014). 
http://www.tdpf.org.uk/resources/publications/drug-decriminalisation-portugal-setting-record-
straight 01. March 2019. 
118 WHO 2016 p. 172.
119 EMCDDA 2019 p. 93.
120 Hughes and Stevens 2010 p. 1917; Hughes and Stevens, A resounding success or a disastrous 
failure: Re-examining the interpretation of evidence on the Portuguese decriminalisation of 
illicit drugs, (31) Drug and Alcohol Review (2012) pp. 101-113 (112 f.); Murkin 2014 p. 3; 
Murkin, Will drug use rise? Exploring a key concern about decriminalising or regulating drugs, 
Transform (2016) https://transformdrugs.org/wp-content/uploads/2020/07/Use-report-2016.
pdf; Streck, 15 Jahre entkriminalisierte Drogenpolitik in Portugal, Telepolis (2016) under https://
www.heise.de/tp/features/15-Jahre-entkriminalisierte-Drogenpolitik-in-Portugal-3224495.html 
31. August 2020. 
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Indications of the effects of a regulated market are available in the US, but data provide 
limited evidence because adolescents under 21 are subject to total prohibition in all 
states that have legalised cannabis.121 Results from the 2018 National Survey of Drug 
Use and Health Substance Abuse by the Mental Health Services Administration122 show 
despite legalisation in further US states123 that cannabis use (12-months prevalence) 
among 12 to 17 year-olds in 2018 was lower than the percentages in 2002-2004 and 
in 2009-2013, but it was similar to the percentages in 2005-2008 and in 2014-2017. 
Consumption has increased only among those over 26 and little among those 18 to 
25.124 Colorado, the first state to legalise marijuana by referendum in 2012, did not 
exhibit any differential change in perceived harmfulness or past-month adolescent 
marijuana use following legalisation.125 
Canada decriminalised cannabis use in October 2018 with the so-called Cannabis 
Act (C4525). This legalised the possession of a maximum of 30 grams for adults. 
Canada has established a national statistical system to measure the social and 
economic impact of the legalisation of cannabis. The National Cannabis Survey 
(NCS) has been conducted since February 2018 so the first data on the consumption 
121 Barsch, Effekte und Nebeneffekte der Umsetzung der Regulierung von Marihuana in den USA: 
Stand Herbst 2016. [Effects and side effects of the implementation of the regulation of marijuana 
in the USA: Status autumn 2016] in akzept e.V. Bundesverband für akzeptierende Drogenarbeit 
und humane Drogenpolitik, Deutsche AIDS-Hilfe, JES e.V. Bundesverband [Federal Association for 
Acceptable Drug Work and Human Drug Policy, German AIDS Aid, JES e.V. Bundesverband], eds. 
5. Alternativer Drogen- und Suchtbericht 2018 (Alternative Drug and Addiction Report 2018) 
pp. 67-75 (71). 
122 SAMHSA (Substance Abuse and Mental Health Services Administration) (2019). Key substance 
use and mental health indicators in the United States: Results from the 2018 National Survey on 
Drug Use and Health (NSDUH) (HHS Publication No. SMA 17-5044, NSDUH Series H-52). 
Rockville, MD: Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental 
Health Services Administration. https://www.samhsa.gov/data/ 01. September 2020 p. 14.
123 The District of Columbia and 11 states -- Alaska, California, Colorado, Illinois, Maine, 
Massachusetts, Michigan, Nevada, Oregon, Vermont and Washington -- have adopted the most 
expansive laws legalising marijuana for recreational use: https://www.governing.com/gov-data/
safety-justice/state-marijuana-laws-map-medical-recreational.html 31. August 2020.
124 SAMHSA 2019 p. 14.
125 Cerdá, M. et al., Association of State Recreational Marijuana Laws With Adolescent Marijuana 
Use, 171(2) JAMA Pediatric (2017) pp. 142-149. HIDTA (Rocky Mountain High Intensity Drug 
Trafficking Area) (2019). The legalization of marijuana in Colorado: The Impact. https://rmhidta.
org/files/D2DF/FINAL-Volume6.pdf. 31.08.2020. Tormohlen et al., Changes in prevalence 
of marijuana consumption modes among Colorado high school students from 2015 to 2017, 
173(10) JAMA Pediatric (2019) pp. 988-989.
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of cannabis are available. The changes in consumption were very moderate.126 Overall 
cannabis use had increased from 14.9% (2018) to 16.8% (2019), particularly among 
males and adults aged 25 and older. Daily or almost daily use remained stable at 6.0%, 
as did the prevalence of driving within 2 hours of consumption (13.2%). Canadians 
report increasingly to obtain cannabis from legal sources instead of illegal sources or 
relying on friends/family. NCS study suggests that use among Canadian youth has 
not increased.127
Hints of declining consumption rates by US and Canadian adolescents could indicate 
reduced availability. About one-third of 16-year-olds in 35 European countries report 
cannabis is readily or very readily available.128 Availability rates span 5% to 50%. 
Looking again at European Countries with different drug policies, 41% of French, 42% 
of Dutch, 50% of Czech, and 31% of Portuguese adolescents indicate easy availability. 
As shown, however, consumption among adolescents diverges significantly, and 
correlations between drug policy and availability (the more repressive the lower) are 
not provable. Also, availability of a drug is embedded amid complex conditions. For 
example, young people in a prohibitive model may find it easier to obtain drugs because 
prohibition triggers black markets. Contrary to expectations of prohibitionists, prices 
in Colorado and Washington have fallen since legalisation, and prison sentences for 
distributing unlicensed cannabis have declined facts taken as evidence that black 
markets are increasingly unable to compete with legal trade.129 There seems no 
connection between regulation policy, greater availability and consumption among 
adolescents.130
Even in Sweden, which is often cited from prohibitionists as an example of sup-
posedly successful prohibition strategies due to its relatively low prevalence rates, 
repressive drug policy does not explain consumption rates.131 The average amount 
126  Rotermann, What has changed since cannabis was legalized?, 31(2) Health Reports (2020) pp. 
11-20. Rotermann and Macdonald, Analysis of Trends in the Prevalence of Cannabis Use in 
Canada, 1985 to 2015, 29(2) Health Reports (2018) pp. 10-20.
127 Rotermann 2020 p. 17.
128 ESPAD 2016 p. 30.
129 Boyd, Cannabis-Legalisierung in Kanada: „Bill C-45“ - Chancen und Probleme [Cannabis 
Legalisation in Canada: “Bill C-45” - Chances and Problems] in akzept e.V et al. [Federal 
Association for Acceptable Drug Work et al.], eds. 5. Alternativer Drogen- und Suchtbericht 
2018 (5th Alternative Drug and Addiction Report 2018) pp. 59-66 (64).
130 GCDP (Global Commission on Drug Policy), Taking Control: Pathways to Drug Policies That 
Work, Global Commission on Drug Policy (2014) p.8.  http://www.globalcommissionondrugs.
org/wp-content/uploads/2016/03/GCDP_2014_taking-control_EN.pdf  01. March 2019; DG-
Sucht 2015 p. 3; Gantner 2016 pp. 55-56.
131  Rolles and Murkin. Drug policy in Sweden: a repressive approach that increases harm, 
Transform (2014) p. 2 http://www.tdpf.org.uk/resources/publications/ drug-policy-sweden-
repressive-approach-increases-harm 19. March 2021.
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of cannabis consumed annually by intensive users is second highest in Sweden (363 
g; after England/Wales 374 g), and lowest in Portugal (184 g).132 Not to mention the 
high mortality rate in Sweden, which reflects only tentative Harm Reduction (HR) 
efforts.133 Obviously, consumption rates are embedded in complex economic, social, 
and cultural factors.
3.4 Black markets and costs of prohibition
The stimulation of the cannabis black market leads to negative consequences for the 
consumers.134 While in Sweden, for example, 52% of cannabis users state that they can 
buy other hard drugs where they buy cannabis, only 26% of Czechs or 14% of Dutch 
people state this. The black market is therefore particularly dangerous for young 
people who simply come into contact with hard drugs and have no information about 
the composition and active ingredients of the cannabis they buy. Even though Dutch 
drug policy has often been criticised, evaluations have shown that the approach of 
separate markets can be seen as positive and that the main objectives of prevention 
and risk minimisation have been partially achieved.135 The use of hard drugs among 
young people is low, illness and mortality rates among drug addicts are stable and 
low, and there is no increase in the consumption of soft drugs. Nevertheless, the 
World Commission points out that the negative effects of the black market cannot 
be countered by decriminalisation models.136 Prohibited production in turn leads to 
black market problems and organised crime, which is discussed in the Netherlands 
under the ‘back-door problem’. In addition, there remains a risk for the consumer. 
In order to reduce the harm caused by drug use in the long term, governments must 
think about suitable market regulation models and consistently regulate access by 
means of age limits and other security measures.137
132 Trautmann, Kilmer and Turnbull, Further insights into aspects of the EU illicit drugs market 
(Verlag 2013) p. 23.
133 With 92 drug-related deaths per 100,000 inhabitants, Sweden is the European leader after 
Estonia. European Drug Report 2019. https://www.statista.com/chart/10320/drug-deaths-in-
europe/ 03. September 2020.
134  Flöter and Pfeiffer-Gerschel 2012 p. 40.
135 Ooyen-Houben, Gebrauch illegaler Drogen und die niederländische Drogenpolitik: Überblick 
und Bewertung [Use of illicit drugs and Dutch drugs policy: overview and evaluation], (20) 
Soziale Probleme) (2009) pp. 57-89; Rolles, Cannabis policy in the Netherlands: moving forwards 
not backwards, Transform (2014) http://www.tdpf.org.uk/resources/publications/cannabis-
policy-netherlands-moving-forwards-not-backwards 01. March 2019.
136 GCDP 2016 p. 33.
137 Cf. Rolles, Nach dem Krieg gegen die Drogen: Modelle für einen regulierten Umgang [After the 
War on Drugs: Blueprint for Regulation], Transform (2009) p. 23 ff; Stöver and Plenert 2013 p. 
38 ff; GCDP 2016 p. 33; GCDP 2018 p. 7.
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The workload of the German police caused by cannabis offences leads to high costs. 
Since most consumer offences are dismissed (§ 31a BtMG), there are less resources 
available to prosecute serious offences. Results of a recent survey among police 
officers in Hamburg show that the attitudes of criminal detectives (contrary to 
the local police officers) have changed since the 1990s and that prohibition is not 
considered effective. Although 83.1% of the officers interviewed in this survey focus 
on drug trafficking, this does not change the fact that police officers cannot look the 
other way when dealing with consumer offences.138 This is confirmed by the annually 
increasing number of consumption-related offences in the PKS.139 It is therefore 
not surprising that the Federation of German Criminal Investigators is currently 
reiterating its demand, which was made for several years now, for a non-repressive 
drug policy when dealing with consumers.140 The main argument is that the resources 
released could be used to intensify the fight against organised crime in the drugs field. 
As shown, organised criminal control of production and supply cannot be broken 
by police means, and a strategy of prohibition promotes it. The cannabis market is 
large, profitable, organised, and characterised by violence and associated crimes.141 
Technological innovations raise production volumes and product potency.142 The 
market is – 1% of Europeans consume cannabis daily143 – and was historically not 
influenced by criminalisation strategies. 
Drug consumption does burden healthcare,144 but no reliable data yet indicate that 
regulation elevates that burden.145 Moreover, tax revenues from regulated markets 
create resources for preventive measures that could counteract consumption and 
exert positive effects on healthcare system. Criminalisation has no demonstrable 
positive impact on consumption and availability of cannabis.146 Lifetime prevalence 
of cannabis use in Germany, for example, rose until the mid-2000s despite existing 
138 Kemme 2018.
139 BKA 2019 p. 154.
140 Site of the Federation of German Criminal Investigators, 31.07.2020. „We are in favour of 
decriminalising consumers and strengthening the protection of minors”. https://www.bdk.
de/der-bdk/was-wir-tun/aktuelles/wir-sind-fuer-entkriminalisierung-der-konsumenten-und-
verstaerkten-jugendschutz 19. March 2021. 
141  EMCDDA and Europol 2019 p. 97.
142 Ibid p. 99.
143 Ibid. p. 98.
144 Effertz, Verheyen and Linder, Ökonomische und intangible Kosten des Cannabiskonsums in 
Deutschland [Economic and intangible costs of cannabis use in Germany] (62) Sucht (2016) pp. 
31-41. 
145  As claimed by Duttge and Steuer 2014 p.183; 2015, 802, Thomasius in Duttge et al. 2017 p. 39.
146 Haucap, Auch der Fiskus profitiert: Der Nutzen einer Cannabislegalisierung in Deutschland, 
Akzept e.V., eds. 6. Alternativer Drogenbericht (2019) pp. 112-119.
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prohibition.147 According to the Global Commission on Drug Policy148 there is no 
justification for a repressive drug policy. Indeed, drug prohibition is regarded as a 
failure because black markets generate social damage.149 
Furthermore, a tightening of prohibition would result in higher costs on the supply 
side to continue to act undetected on the black market. These costs would also be 
reflected in prices for consumers. Thus, more resources would have to be spent in 
illegal markets, whereas legalisation and taxation could lead to revenues on the side 
of the state.150 Regulated markets or even the downgrading of consumption to an 
administrative offence lead to a massive reduction in the burden on law enforcement 
agencies.151 Even if black markets cannot be eliminated, they can be reduced 
significantly,152 thereby releasing resources for prevention or to fight serious and 
organised crimes. According to Haucap et al., an amount of 2.66 billion euros can be 
raised by legalising cannabis, on the one hand through tax revenues and on the other 
through saved expenditure.153
147 Orth, Die Drogenaffinität Jugendlicher in der Bundesrepublik Deutschland 2015. Rauchen, 
Alkoholkonsum und Konsum illegaler Drogen: aktuelle Verbreitung und Trends. BZgA-
Forschungsbericht. [The drug affinity of young people in the Federal Republic of Germany 
2015. Smoking, alcohol consumption and use of illegal drugs: current distribution and trends. 
BZgA research report.] (Bundeszentrale für gesundheitliche Aufklärung 2016) p. 62.
148 GCDP (Global Commission on Drug Policy). Advancing Drug Policy Reform: a new 
approach to decriminalization, Global Commission on Drug Policy (2016). http://www.
globalcommissionondrugs.org/wp-content/uploads/2016/11/GCDP-Report-2016-ENGLISH.
pdf  01. March 2019. GCDP 2014.
149 GCDP (Global Commission on Drug Policy), Regulation. The Responsible Control of Drugs, 
Global Commission on Drug Policy (2018) http://www.globalcommissionondrugs.org/wp-
content/uploads/2018/09/ENG-2018_Regulation_Report_WEB-FINAL.pdf  19 March 2021; 
GCDP 2014, 2016; Stöver and Plenert 2013 p. 44.
150 Scharnhorst and Honecker 2019.
151 Flöter and Pfeiffer-Gerschel, Ökonomische Auswirkungen der Prohibition [Economic 
Impact of Prohibition] in Entkriminalisierung von Drogenkonsumenten – Legalisierung von 
Drogen. [Decriminalisation of drug users - legalisation of drugs.], eds. Gerlach and Stöver 
(Fachhochschulverlag Frankfurt am Main 2013) pp. 33-47 (40 f.); Gaßmann, Die Cannabis-
Diskussion aus der Perspektive von Prävention und Suchthilfe [The cannabis discussion from the 
perspective of prevention and addiction.] (6) Suchttherapie (2005) pp. 97-101 (100); Kemme, 
Die Zeit ist reif. Betrachtungen zur Cannabisregulierung unter besonderer Berücksichtigung 
polizeilicher Belange in Mittler zwischen Recht und Wirklichkeit. Festschrift für Arthur Kreuzer 
zum 80. Geburtstag, eds. Bartsch et al. (Verlag für Polizeiwissenschaft 2018) pp. 313-348; 
Stöver and Penert 2013 p. 18; Simon and Hughes, Cannabis und Drogenrecht in Europa: 
Gesetzeslage, Umsetzung und aktuelle Diskussionen zur Weiterentwicklung, (1) Sucht aktuell 
(2015) pp. 18-26 (21–23); Pollähne 2016 p. 78.
152 Caulkins et al. 2015 p. 63; Caulkins et al., Considering Marijuana Legalization: lnsights for 
Vermont and Other Jurisdictions (Rand cooperation 2015). 
153 Haucap et al., Die Kosten der Cannabis-Prohibition in Deutschland, DICE Consult (2018).
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4. Political advances
More than 20 years after the 1994 Federal Constitutional Court decision, the 
entire German narcotics law was put to test when 122 criminal law professors (the 
Schildower Kreis) submitted a resolution to the Bundestag, draw legislators’ attention 
to unintended harmful side effects and consequences of criminalising cannabis in 
2014. In the resolution, they demanded to check the effectiveness of the drug law. 
They criticised the unsuccessful criminal prosecution of drug demand and supply and 
noted that Taliban terrorism in Afghanistan is mainly financed via black market heroin 
and hashish. This gigantic black market ‘generates […] other subsequent criminal 
activity and [has] destabilising effects on global financial markets just as [on] national 
economies’. Science had proven that the danger of drugs would be mastered ‘better 
by health-juridical regulation […] as well as with adequate youth welfare measures’.154 
The German Society for Addiction Medicine (Deutsche Gesellschaft für Suchtmedizin 
DGS) joined the resolution in February 2015. The Federation of German Criminal 
Investigators (Bund Deutscher Kriminalbeamter BDK)155 and The New Judges 
Association (Neue Richtervereinigung) also advocate legalisation.156 Thomas Fischer, 
probably the best-known author of German criminal code commentaries and former 
presiding judge at the Federal Criminal Court for Criminal Matters, comments the 
criminal sections on cannabis use as follows: An ‘unbiased, rational view (...) should 
no longer ignore’ that ‘the prohibition policy of intoxicants has failed in terms of 
criminal policy, but also criminal law. A society that has 5 percent of its members 
criminalised because of consumption of intoxicants, while at the same time another 
30 percent of the population legally and state-sponsored drinks or smokes itself to 
death is obviously irrational’.157
In 2015, opposition fractions in the Bundestag, the Left Party and the Green Party, filed 
a joint petition to review criminal drug law based on this resolution and to seek support 
from the Social Party. They drafted a Cannabis Control Bill (Cannabiskontrollgesetz, 
CannKG) to remove cannabis from criminal restrictions under BtMG and to open 
154 The resolution can be found at http://schildower-kreis.de/resolution-deutscher-
strafrechtsprofessorinnen-und-professoren-an-die-abgeordneten-des-deutschen-bundestages/ 
19. March 2021.
155 The BDK chairman André Schulz claimed that the ban on cannabis was “historically arbitrary 
and has so far been neither intelligent nor effective”: https://www.spiegel.de/panorama/justiz/
cannabis-bund-deutscher-kriminalbeamter-fordert-ende-des-verbots-a-1191381.html 19. 
March 2021.
156 Opinion of the New Judges Association on the draft of a cannabis control law (CannKG), Bundestag 
printed matter (BT-Drs.) 18/4204 https://dip21.bundestag.de/dip21/btd/18/042/1804204.pdf 19. 
March 2021.
157 Fischer (ed.), StGB, 63rd edition (2018), Comment before § 52 StGB.
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a strictly controlled legal market for cannabis.158 This would take better account 
of the protection of minors than before, since it is only in such a market that the 
ban on selling cannabis to minors can be effectively monitored. A good cannabis 
policy regulates the cannabis market in such a way that the protection of minors is 
strengthened, and the risks are reduced as much as possible. Facing opposition from 
the Christian Party and the Social Party, the draft was rejected in 2017.
In December 2017, the Free Democratic Party joined the cannabis-liberalisation-
movement and proposed in a ‘small request’ to the government for a controlled legal 
market in cannabis and model projects for its free use.159 In its application the FDP 
parliamentary group also advocated enabling model projects for free cannabis use. 
The fight against cannabis use by repression had failed. It was therefore time to break 
new ground in addiction prevention, the group argued. The aim had to be to control 
the spread of cannabis and to improve public health and youth protection.160
In February 2018, the Green Party brought in the Cannabis Control Bill again, claiming 
it was justified by a failed cannabis drug policy. Cannabis was then Germany’s most 
common illegal drug, consumed by an estimated 3.1 million adult citizens.161 In the 
same month, the parliamentary group of the Left Party also submitted a draft. They 
also see the cannabis ban policy as a failure. According to their application ‘Health 
protection instead of law enforcement - For a progressive use of cannabis, cannabis 
is the most commonly used illegal drug. This is countered by a drug policy based 
on bans, which is ideologically motivated and would ignore the realities of life of 
the citizens. The group calls for the possession of cannabis for personal use and to 
strengthen the pillars of drug prevention, advice and treatment in drug policy over 
the pillar of repression and stigmatisation.162 The requests of the opposition groups in 
the Bundestag were rejected by the government majority.
In February 2020 the fraction of the Social Democratic Party (SPD) in the German 
Bundestag (coalition partner in the current German government) has also spoken 
out in favour of a different cannabis policy. It had decided to abandon the previous 
158 Bundestag printed matter (BT-Drs.) 18/4204 4. March 2015 http://dip21.bundestag.de/dip21/
btd/18/042/1804204.pdf 19. March 2021.
159 Bundestag printed matter (BT-Drs.) 19/181 5. December 2017 https://dip21.bundestag.de/
dip21/btd/19/001/1900181.pdf 19. March 2021.
160 Bundestag printed matter (BT-Drs.) 19/515 24. January 2018 https://dip21.bundestag.de/dip21/
btd/19/005/1900515.pdf 19. March 2021.
161 Bundestag printed matter (BT-Drs.) 19/819 20. February 2018 http://dip21.bundestag.de/dip21/
btd/19/008/1900819.pdf 19. March 2021.
162 Bundestag printed matter (BT-Drs.) 19/832 21. February 2018, https://dip21.bundestag.de/
dip21/btd/19/008/1900832.pdf 19. March 2021.
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cannabis ban policy in Germany, the fraction stated.163 The possession of small amounts 
of cannabis for personal consumption should no longer be prosecuted and instead 
only be treated as an administrative offence. Model projects should be made possible 
to test legal and regulated supply of cannabis to consumers. Several applications of 
German cities164 in this regard have so far been regularly rejected by the responsible 
Federal Institute for Medicinal Products and Medical Devices (Bundesinstitut für 
Arzneimittel und Medizinprodukte ‘BfArM”) due to the existing legal situation.165
The coalition partner in the current government, the Christian Democratic Party 
(CDU/CSU), sticks with the argument that cannabis is a gateway drug and damages 
the brain.166  As for the German population according to a poll by Infratest Dimap on 
behalf of the German association Deutscher Hanfverband in the year 2019 44% of 
Germans are in favour of legalisation of cannabis for adults.167 
5. New Submission order to the German Federal Constitutional Court 
in April 2020
In addition to the legislative initiatives, there are also current efforts by the advocates of 
decriminalisation to achieve their goals by establishing the unconstitutionality of the 
criminal norms. In April 2020, the Criminal District Court of Berlin-Bernau justified 
a submission order to the Federal Constitutional Court (BVerfG) with the fact that 
the prohibition of cannabis is unconstitutional.168 This is the conclusion reached by 
criminal judge Andreas Müller from the Bernau district court (near Berlin). Does 
a German court consider a law, the validity of which is important for the decision 
unconstitutional, it suspends the proceedings and gets the decision of the Federal 
Constitutional Court. 
163 Position Paper of the fraction of the Social Democratic Party (SPD) in the German Bundestag, 
11th of February 2020, https://www.spdfraktion.de/system/files/documents/positionspapier-
cannabis-neue-wege-gehen-20200211.pdf 19. March 2021.
164 Düsseldorf, Münster, Bremen, Berlin Kreuzberg and most recently the state of Berlin.
165 The application of Berlin was rejected in April 2020, Press release of the State of Berlin: https://
www.berlin.de/aktuelles/berlin/6136312-958092-bundesinstitut-lehnt-cannabismodellversu.
html 19. March 2021.
166 The drug commissioner of the federal government from the CSU also takes this view https://
www.drogenbeauftragte.de/ 19. March 2021.
167 Poll of the Infratest Dimap on behalf of Deutscher Hanfverband in 2019: https://hanfverband.
de/sites/default/files/2019.09.02_hanfverband_cannabis_graf.pdf 19. March 2021.
168 Js 7322/19 (346/19) Criminal District Court of Berlin-Bernau, decision in criminal 
matters of 18. September 2019. http://www.ag-bernau.brandenburg.de/media_fast/4190/
Vorlagebeschluss%20vom%2020.04.2020%20-%20anonymisiert%20-.16675354.pdf 19. 
March 2021.
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In this case, a 24-year-old mechanical engineering student purchased 2,6 g of cannabis 
resin in the Görlitzer Park (Berlin) and was subsequently subjected to a police check. 
Since the young man already had been taken with resin, the prosecutor refused to 
dismiss the case and demanded a fine of 150 euros. 
For a new application to the Federal Constitutional Court to be authorised, the 
district court must prove that there have been ‘new facts’ since 1994, when the Federal 
Constitutional Court ruled on the question for the first time.169 In 2004, when the 
same judge Müller from the Bernau district court had already filed such a submission 
order, the court had found it to be inadmissible, among other reasons, because new 
facts ‘which would enable a decision that diverged from the earlier decision of the 
Federal Constitutional Court’ had not been stated.170Among other things, judge 
Müller now states that there are now indications that the dangerousness of cannabis is 
to be assessed differently than before: ‘The clearest and most recent expression of the 
re-evaluation of the dangerousness of cannabis is found in the critical report on the 
current classification of cannabis by the Standard Agreement on Narcotics, published 
in 2018 by the WHO Expert Committee on Drug Dependence’.171 The committee 
submitted a letter to the Secretary General of the United Nations, António Guterres, 
with reference to Art. 3 of the Single Convention on Narcotic Drugs, which noting 
that preparations based on pure Cannabidiol (CBD) should no longer be listed in 
international drug control agreements.172
Further, Müller refers to more recent evidence, according to which the ‘general 
assumption that cannabis use has a deterioration in mental health’, cannot be proven. 
‘It can be shown that stronger problematic people consume particularly frequently, 
evidence of a harmful substance effects of cannabis, however, cannot be found’ he 
states. It should also be noted, ‘that in light of the millions relatively few are treated in 
outpatient or inpatient settings because of the main diagnosis cannabis’.173
169 BVerfGE 90, 145.
170 BVerfG, 29. June 2004, 2 BvL 8/02 -, para. 1-50, http://www.bverfg.de/e/lk20040629_2bvl000802.
html 19. March 2021.
171 2 Cs 226 Js 7322/19 (346/19) p. 14 (Criminal District Court of Berlin-Bernau, decision in 
criminal matters of 18 September 2019). http://www.ag-bernau.brandenburg.de/media_
fast/4190/Vorlagebeschluss%20vom%2020.04.2020%20-%20anonymisiert%20-.16675354.
pdf 19. March 2021.
172 Letter of the WHO Expert Committee on Drug Dependence from 2019, https://faaat.net/wp-
content/uploads/ECDD-cannabis-final-outcome.pdf 19. March 2021.
173 2 Cs 226 Js 7322/19 (346/19) p. 18 (Criminal District Court of Berlin-Bernau, decision in 
criminal matters of 18. September 2019) http://www.agbernau.brandenburg.de/media_
fast/4190/Vorlagebeschluss%20vom%2020.04.2020%20-%20anonymisiert%20-.16675354.
pdf 19. March 2021.
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Whether the 140-page submission order now passes the hurdle of the admissibility 
test, is considered open by observers. Essentially it depends on whether the District 
Court has presented enough facts to convince the Federal German Court that a new 
situation has arisen on the subject of cannabis that could be considered legally.
6. Summary and conclusions
The current German legal system of cannabis control is based on strict prohibition 
of cannabis outside medical or scientific use. As in many other western countries, an 
increasing number of German scientists and citizens and therefore also a growing 
number of political parties are of the opinion that the Narcotics Act in Germany 
needs an urgent review (see section 2). 
As shown above, there are numerous new studies on cannabis, making it one of the 
best researched drugs. Studies classify the health and social risk of cannabis as low, 
especially for recreational use by adults (see section 3.1 and 3.2). It can be regarded 
as empirically proven that the recreational use of cannabis is relatively harmless 
compared to the currently legal drugs alcohol and nicotine.
As with any other drug, children and young people are particularly vulnerable and 
must be protected (see Section 3.3). The use of cannabis in childhood and adolescence 
can have both physical and psychological consequences. But, the results of the 
present paper do not allow the conclusion that prohibition-oriented drug policies 
prevent young people of using drugs or that more liberal policies lead to an increase 
in prevalence rates. Although prohibitionists claim that there is a link between 
national drug strategy and consumption rates, there is no empirical evidence for such 
a correlation. The comparison of countries with different drug policy approaches 
reveals that cannabis use among young people seems to be influenced by a number of 
other factors. Even in Sweden, which is often cited from prohibitionists as an example 
of supposedly successful prohibition strategies due to its relatively low prevalence 
rates, repressive drug policy does not explain consumption rates. Decriminalisation 
has neither increased consumption rates in Portugal nor reduced the age of onset in 
the Czech Republic.174 The decisive factors are ancillary, including measures geared to 
prevention, addiction therapies, and reducing damage.
174 Červený, Chomynová, Mravčík et al. ‘Cannabis decriminalization and the age of onset of 
cannabis use’. International Journal of Drug Policy, (43) (2017) pp. 122-129 (128).
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Consumers look for their own ways. In this respect, the demand side - not the 
supply side - is identified as important source of problems and drug policy starting 
point.175  In its reports, the Global Commission on Drug Policy makes it more than 
clear that states must finally abandon the wishful thinking of a drug-free society by 
prohibition; prohibitive drug policy models have failed because they can neither 
prevent nor reduce consumption and dependence.176 In this sense, the German 
Society for Addictive Medicine,177 the German Head Office for Addiction Issues178 
and, as already mentioned, a majority of professors of criminal law in Germany (the 
Schildower Kreis) recommend that the German Narcotics Act be reviewed, as the law’s 
goal of excluding the misuse of narcotics and the development or maintenance of 
narcotic dependence as far as possible has not been achieved. In addiction medicine, 
the dogma of abstinence already fell 20 years ago, so that it is primarily a matter 
of ensuring the healthiest possible survival, reducing consumption and extending 
abstinent periods.179
The stimulation of the cannabis black market leads to negative consequences for 
the consumers.180 The black market is particularly dangerous for young people 
who simply come into contact with hard drugs and have no information about the 
composition and active ingredients of the cannabis they buy. Even though Dutch 
drug policy has often been criticised, evaluations have shown that the approach of 
separate markets can be seen as positive and that the main objectives of prevention 
175 Raschke, Freigabe illegaler Drogen: Ethisch geboten oder unverantwortlich? – Pro (Release of 
Illicit Drugs: Ethical Command or Irresponsible Attitude? – Pro), Suchttherapie, (09) (2008) pp. 
164-169 (167).
176 Cf. GCDP, 2014, 2016, GCDP. The World Drug Perception Problem. (2017) http://www.
globalcommissionondrugs.org/wp-content/uploads/2018/01/GCDP-Report-2017_Perceptions-
ENGLISH.pdf  01. March 2019. GCDP 2018, 2019, GCDP, Enforcement of Drug Laws. 
Refocusing on Organized Crime Elites. (2020) https://www.globalcommissionondrugs.org/wp-
content/uploads/2020/06/2020report_ EN_web_100620.pdf  03. September 2020.
177 DGS (Deutsche Gesellschaft für Suchtmedizin e.V.), Warum das Betäubungsmittelgesetz (BtMG) 
aus suchtmedizinischer Sicht auf den Prüfstand gehört. [Why the Betäubungsmittelgesetz 
(BtMG) belongs from the point of view of addiction medicine to the test.] Suchttherapie, (15) 
(2014) p. 49. 
178 DHS (Deutsche Hauptstelle für Suchtfragen e.V.) (2015). Cannabispolitik in Deutschland. 
Maßnahmen überprüfen. Ziele erreichen. [Cannabis policy in Germany. Check measures. 
Achieve goals.] http://www.dhs.de/fileadmin/user_upload/pdf/news/Cannabispolitik_in_
Deutschland.pdf 01. March 2019. 
179 DGS 2014 p. 49.
180 Flöter and Pfeiffer-Gerschel 2012 p. 40.
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and risk minimisation have been partially achieved.181 The use of hard drugs among 
young people is low, illness and mortality rates among drug addicts are stable and 
low, and there is no increase in the consumption of soft drugs. Nevertheless, the 
World Commission points out that the negative effects of the black market cannot 
be countered by decriminalisation models.182 Prohibited production in turn leads to 
black market problems and organised crime, which is discussed in the Netherlands 
under the ‘back-door problem’. In addition, there remains a risk for the consumer. 
In order to reduce the harm caused by drug use in the long term, governments must 
think about suitable market regulation models and consistently regulate access by 
means of age limits and other security measures.183
It is sometimes argued by prohibitionists in Germany that repression is after all 
only one pillar of a balanced cannabis policy, which already (sufficiently) takes into 
account the other pillars of prevention, treatment and HR. Only in recent years, a 
number of therapy measures and intervention programmes have been established in 
the cannabis field. However, there is still a lack of adequate consideration of feasible 
HR measures.184 In Germany, the implementation of both individual and structural 
HR approaches is very limited.185 It is not - as is sometimes claimed - predominantly 
the law enforcement agencies that place young people in programmes. Rather, the 
illegality of cannabis makes access to early intervention programmes via other 
potential placement partners such as schools, parents, companies, youth welfare 
services, vocational preparation courses or youth leisure centres more difficult,186 
so that many young people in need of help remain unreached. In addition, it is 
known from addiction aid that especially socially disadvantaged and psychologically 
vulnerable young people, as a result of prohibition, reach criminal milieus faster than 
181 Ooyen-Houben, Gebrauch illegaler Drogen und die niederländische Drogenpolitik: Überblick 
und Bewertung  [Use of illicit drugs and Dutch drugs policy: overview and evaluation], Soziale 
Probleme, (20) (2009) pp. 57-89; Rolles, Cannabis policy in the Netherlands: moving forwards 
not backwards. Transform (2014) http://www.tdpf.org.uk/resources/publications/cannabis-
policy-netherlands-moving-forwards-not-backwards 01. March 2019.
182 GCDP 2016 p. 33.
183 Cf. Transform. Nach dem Krieg gegen die Drogen: Modelle für einen regulierten Umgang 2009 
p. 23 ff; Stöver and Plenert 2013 p. 38 ff; GCDP 2016 p. 33; GCDP 2018 p. 7.
184 Bücheli, Schadensminimierung und Cannabis: Ist Safer Use möglich?, Suchtmagazin (2), 
(2014) pp. 47-51; Manthey, Stöver and Meyer-Thompson, Cannabis und Schadensminderung 
in Deutschland (Cannabis and Harm Reduction in Germany), Suchttherapie, (19) (2018) pp. 
148–158. 
185 Manthey et al. 2017.
186 DGSAS (Deutsche Gesellschaft für Soziale Arbeit in der Suchthilfe) (2015). Stellungnahme 
„Erfahrungen in der Frühintervention bei jugendlichen Cannabiskonsumenten“. [Statement 
„Experiences in Early Intervention in Juvenile Cannabis Consumers“] www.dgsas.de/
downloads/Stellungnahme%20Cannabis%20BMG_DGSAS _23.2.15.pdf 03. March 2018, p. 
2; Gantner 2016 p. 56.
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others.187 A cannabis policy that continues to insist on the necessity of the pillar of 
repression will not be able to protect the health of consumers sufficiently in the long 
term. Open, targeted prevention work will be hindered; people will be discouraged 
from seeking help. With regard to alcohol and nicotine, it is already known that 
regulated markets offer the most effective protection when the framework conditions 
are adapted with stricter rules and increased educational work.188 Positive trends in 
alcohol and cigarette consumption among young people can currently be observed.189 
According to youth researchers, the image of these drugs has deteriorated, which 
suggests a connection with educational campaigns. 
It is certainly true that the impact of a market regulating all drugs cannot yet be 
conclusively assessed. Moreover, the European Monitoring Centre for Drugs and 
Drug Addiction rightly points out that developments and evaluations in other parts 
of the world need not be directly transferable to the European context.190 However, 
a proportionality assessment with regard to cannabis prohibition leads to a clear 
result. The damage to society as a whole caused by prohibition can only be effectively 
countered by a regulated market, especially for the protection of young people. 
Overall, a strictly regulated market would be expected to provide positive economic, 
social and health incentives. 
Currently two approaches of changing drug policy with regard to cannabis are 
being pursued: One approach regards legislative initiatives by political parties to 
decriminalise the use of cannabis. Already several times in recent years a Cannabis 
Control Bill aiming to liberalise cannabis use has been introduced to German 
Parliament, still lacking a political majority. Nevertheless the number of political parties 
in favour of a changed policy increased during the last years. A second approach can 
be found in the submission order to the Federal Constitutional Court presenting ‘new 
facts’ with the aim of declaring the current prohibition (German Narcotics Act) law 
unconstitutional. Such order was filed to the Federal Constitutional Court in 2020. 
Both approaches are based on new scientific knowledge on the harms of cannabis use 
physically, psychically and economically (‘new facts’).
While chances of success of the current application to the Federal Constitutional 
Court do not appear predictable, the political climate could change in the near future 
towards a change in the German Narcotic Act. In Germany - as in many other west-
ern countries - drug policy reform towards cannabis seems increasingly likely.
187 DGSAS 2015 p. 3; Gantner 2016 p. 56.
188 Cf. Transform 2009 pp. 102 ff.; Stöver and Plenert 2013 p. 44.
189 Orth and Merkel 2020 pp. 30, 45.
190 EMCDDA 2017 p. 12.
